Arcturus Therapeutics Statistics Share Statistics Arcturus Therapeutics has 27.12M
shares outstanding. The number of shares has increased by 0.29%
in one year.
Shares Outstanding 27.12M Shares Change (YoY) 0.29% Shares Change (QoQ) 0% Owned by Institutions (%) 98.2% Shares Floating 24.83M Failed to Deliver (FTD) Shares 7,569 FTD / Avg. Volume 1.68%
Short Selling Information The latest short interest is 4.48M, so 16.52% of the outstanding
shares have been sold short.
Short Interest 4.48M Short % of Shares Out 16.52% Short % of Float 25.56% Short Ratio (days to cover) 10.21
Valuation Ratios The PE ratio is -5.66 and the forward
PE ratio is -4.29.
Arcturus Therapeutics's PEG ratio is
-0.03.
PE Ratio -5.66 Forward PE -4.29 PS Ratio 3.31 Forward PS 2.7 PB Ratio 1.9 P/FCF Ratio -7.59 PEG Ratio -0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Arcturus Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.67,
with a Debt / Equity ratio of 0.12.
Current Ratio 4.67 Quick Ratio 4.67 Debt / Equity 0.12 Debt / EBITDA -0.37 Debt / FCF -0.47 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $795.34K Profits Per Employee $-465.18K Employee Count 174 Asset Turnover 0.4 Inventory Turnover n/a
Taxes Income Tax -4K Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -39.89% in the
last 52 weeks. The beta is 2.27, so Arcturus Therapeutics's
price volatility has been higher than the market average.
Beta 2.27 52-Week Price Change -39.89% 50-Day Moving Average 13.13 200-Day Moving Average 14.76 Relative Strength Index (RSI) 39.3 Average Volume (20 Days) 451,074
Income Statement In the last 12 months, Arcturus Therapeutics had revenue of 138.39M
and earned -80.94M
in profits. Earnings per share was -3.
Revenue 138.39M Gross Profit 134.84M Operating Income -95.67M Net Income -80.94M EBITDA -77.4M EBIT -80.94M Earnings Per Share (EPS) -3
Full Income Statement Balance Sheet The company has 237.03M in cash and 28.55M in
debt, giving a net cash position of 208.48M.
Cash & Cash Equivalents 237.03M Total Debt 28.55M Net Cash 208.48M Retained Earnings -448.81M Total Assets 331.79M Working Capital 229.38M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -59.75M
and capital expenditures -648K, giving a free cash flow of -60.4M.
Operating Cash Flow -59.75M Capital Expenditures -648K Free Cash Flow -60.4M FCF Per Share -2.24
Full Cash Flow Statement Margins Gross margin is 97.44%, with operating and profit margins of -69.13% and -58.49%.
Gross Margin 97.44% Operating Margin -69.13% Pretax Margin -58.49% Profit Margin -58.49% EBITDA Margin -55.93% EBIT Margin -69.13% FCF Margin -43.64%
Dividends & Yields ARCT does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ARCT is $52.5,
which is 360.9% higher than the current price. The consensus rating is "Buy".
Price Target $52.5 Price Target Difference 360.9% Analyst Consensus Buy Analyst Count 7
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 16, 2017. It was a
backward
split with a ratio of 1:7.
Last Split Date Nov 16, 2017 Split Type backward Split Ratio 1:7
Scores Altman Z-Score 0.63 Piotroski F-Score 2
